Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma

dc.contributor.authorChami, Perla
dc.contributor.authorJarnagin, William R.
dc.contributor.authorAbou-Alfa, Ghassan Khaled
dc.contributor.authorHarding, James J.
dc.contributor.authorKim, Neal
dc.contributor.authorLin, Haibo
dc.contributor.authorEl Homsi, Maria
dc.contributor.authorCrane, Christopher H.
dc.contributor.authorHajj, Carla
dc.contributor.departmentDepartment of Biology
dc.contributor.facultyFaculty of Arts and Sciences (FAS)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:21:18Z
dc.date.available2025-01-24T11:21:18Z
dc.date.issued2023
dc.description.abstractHepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the third-leading cause of cancer-related deaths worldwide. Curative intent treatment options for patients with HCC include liver transplantation, resection and ablation of small lesions. Other potentially curative therapies include cryoablation, microwave ablation and percutaneous alcohol injection. For locally advanced disease, different arterially directed therapies including transarterial chemoembolization and selective internal radiation therapy, plus external beam radiation including three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, stereotactic body radiation therapy and proton beam therapy, are available or studied. Systemic therapies based on checkpoint inhibitors and tyrosine kinase inhibitors are available for the management of metastatic HCC and sometimes for locally advanced disease. Combinations of locoregional therapies with systemic drugs are currently the subject of several clinical trials. © 2023 by the authors.
dc.identifier.doihttps://doi.org/10.3390/cancers15061748
dc.identifier.eid2-s2.0-85151349368
dc.identifier.urihttp://hdl.handle.net/10938/25247
dc.language.isoen
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.ispartofCancers
dc.sourceScopus
dc.subjectAblation
dc.subjectAblative radiation therapy
dc.subjectChemoembolization
dc.subjectCombination therapy
dc.subjectHepatocellular carcinoma
dc.subjectInterventional radiology
dc.subjectProton beam therapy
dc.subjectRadioembolization
dc.subjectStereotactic body radiation therapy
dc.subjectAtezolizumab
dc.subjectBevacizumab
dc.subjectCamrelizumab
dc.subjectDurvalumab
dc.subjectLenvatinib
dc.subjectRivoceranib
dc.subjectSorafenib
dc.subjectTicilimumab
dc.subjectAblation therapy
dc.subjectAngiogenesis
dc.subjectCancer immunotherapy
dc.subjectCancer radiotherapy
dc.subjectCancer staging
dc.subjectCell proliferation
dc.subjectCryoablation
dc.subjectDrug efficacy
dc.subjectDrug safety
dc.subjectExternal beam radiotherapy
dc.subjectFirst-line treatment
dc.subjectHepatectomy
dc.subjectHuman
dc.subjectIntensity modulated radiation therapy
dc.subjectLiver cancer
dc.subjectLiver cell carcinoma
dc.subjectLiver transplantation
dc.subjectMicrowave thermotherapy
dc.subjectMinimally invasive procedure
dc.subjectMonotherapy
dc.subjectNon-surgical locoregional therapy
dc.subjectOverall survival
dc.subjectPortal vein thrombosis
dc.subjectProgression free survival
dc.subjectProton therapy
dc.subjectRadiofrequency ablation
dc.subjectReview
dc.subjectSelective internal radiation therapy
dc.subjectSystemic therapy
dc.subjectVolumetric modulated arc therapy
dc.titleNon-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2023-841.pdf
Size:
696.67 KB
Format:
Adobe Portable Document Format